Publications

  1. Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2017 Dec 11 [Epub ahead of print]
    View PubMed
  2. Mason RJ, Boorjian SA, Bhindi B, Rangel L, Frank I, Karnes RJ, Tollefson MK. The Association Between Sarcopenia and Oncologic Outcomes After Radical Prostatectomy. Clin Genitourin Cancer. 2017 Dec 6 Epub 2017 Dec 06
    View PubMed
  3. Bhindi B, Karnes RJ, Rangel LJ, Mason RJ, Gettman MT, Frank I, Tollefson MK, Lin DW, Thompson RH, Boorjian SA. Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification. J Urol. 2017 Dec; 198 (6):1286-1294 Epub 2017 June 29
    View PubMed
  4. Merrill SB, Boorjian SA, Thompson RH, Psutka SP, Cheville JC, Thapa P, Tollefson MK, Frank I. Oncologic surveillance following radical cystectomy: an individualized risk-based approach. World J Urol. 2017 Dec; 35 (12):1863-1869 Epub 2017 July 06
    View PubMed
  5. Mason RJ, Frank I, Bhindi B, Tollefson MK, Thompson RH, Karnes RJ, Tarrell R, Thapa P, Boorjian SA. Radical cystectomy for recurrent urothelial carcinoma after prior partial cystectomy: perioperative and oncologic outcomes. World J Urol. 2017 Dec; 35 (12):1879-1884 Epub 2017 Sept 14
    View PubMed
  6. Bhindi B, Lohse CM, Mason RJ, Westerman ME, Cheville JC, Tollefson MK, Boorjian SA, Thompson RH, Leibovich BC. Are We Using the Best Tumor Size Cut-points for Renal Cell Carcinoma Staging? Urology. 2017 Nov; 109:121-126 Epub 2017 Apr 12
    View PubMed
  7. Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur Urol. 2017 Nov; 72 (5):660-664 Epub 2017 May 22
    View PubMed
  8. Bhindi B, Carlson RE, Mason RJ, Schulte PJ, Gettman MT, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Leibovich BC, Karnes RJ. Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin. Urology. 2017 Nov; 109:145-152 Epub 2017 Aug 18
    View PubMed
  9. Yang DY, Thompson RH, Zaid HB, Lohse CM, Rule AD, Boorjian SA, Leibovich BC, Cheville JC, Tollefson MK. Severity of Preoperative Proteinuria is a Risk Factor for Overall Mortality in Patients Undergoing Nephrectomy. J Urol. 2017 Oct; 198 (4):795-802 Epub 2017 Apr 08
    View PubMed
  10. Parker WP, Smelser W, Lee EK, Habermann EB, Thapa P, Zaid HB, Frank I, Griebling TL, Tollefson MK, Thompson RH, Holzbeierlein JM, Karnes RJ, Boorjian SA. Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients. Clin Genitourin Cancer. 2017 Aug 01;
    View PubMed
  11. Parker WP, Habermann EB, Day CN, Zaid HB, Frank I, Thompson RH, Tollefson MK, Boorjian SA, Pagliaro LC, Karnes RJ. Adverse Pathology After Neoadjuvant Chemotherapy and Radical Cystectomy: The Role of Adjuvant Chemotherapy. Clin Genitourin Cancer. 2017 Jul 22;
    View PubMed
  12. Bhindi B, Rangel LJ, Mason RJ, Gettman MT, Frank I, Kwon ED, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Impact of Radical Prostatectomy on Long-Term Oncologic Outcomes in a Matched Cohort of Men with Pathological Node Positive Prostate Cancer Managed by Castration. J Urol. 2017 Jul; 198: (1)86-91.
    View PubMed
  13. Gershman B, Meier SK, Jeffery MM, Moreira DM, Tollefson MK, Kim SP, Karnes RJ, Shah ND. Redefining and Contextualizing the Hospital Volume-Outcome Relationship for Robot-Assisted Radical Prostatectomy: Implications for Centralization of Care. J Urol. 2017 Jul; 198: (1)92-99.
    View PubMed
  14. Bailey GC, Frank I, Tollefson MK, Gettman MT, Knoedler JJ. Perioperative outcomes of robot-assisted laparoscopic partial cystectomy. J Robot Surg. 2017 Jun 10;
    View PubMed
  15. Gershman B, Thompson RH, Moreira DM, Boorjian SA, Tollefson MK, Lohse CM, Costello BA, Cheville JC, Leibovich BC. Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis. Eur Urol. 2017 Apr; 71 (4):560-567 Epub 2016 Sept 24
    View PubMed
  16. Parker WP, Davis BJ, Park SS, Olivier KR, Choo R, Nathan MA, Lowe VJ, Welch TJ, Evans JD, Harmsen WS, Zaid HB, Sobol I, Moreira DM, Haloi R, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes RJ, Kwon ED. Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease. Eur Urol. 2017 Mar; 71 (3):340-348 Epub 2016 Sept 03
    View PubMed
  17. Tollefson MK. Editorial Comment. J Urol. 2017 Jan; 197: (1)82.
    View PubMed
  18. Viers BR, Thompson RH, Lohse CM, Cheville JC, Leibovich BC, Boorjian SA, Tollefson MK. Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors. World J Urol. 2016 Dec; 34 (12):1693-1699 Epub 2016 Apr 06
    View PubMed
  19. Parker WP, Tollefson MK, Heins CN, Hanson KT, Habermann EB, Zaid HB, Frank I, Thompson RH, Boorjian SA. Characterization of perioperative infection risk among patients undergoing radical cystectomy: Results from the national surgical quality improvement program. Urol Oncol. 2016 Dec; 34 (12):532.e13-532.e19 Epub 2016 Aug 05
    View PubMed
  20. Westerman ME, Parker WP, Viers BR, Rivera ME, Karnes RJ, Frank I, Tarrell R, Thapa P, Thompson RH, Tollefson MK, Boorjian SA. Malignant ureteroenteric anastomotic stricture following radical cystectomy with urinary diversion: Patterns, risk factors, and outcomes. Urol Oncol. 2016 Nov; 34 (11):485.e1-485.e6 Epub 2016 July 14
    View PubMed
  21. Kaushik D, Boorjian SA, Thompson RH, Eisenberg MS, Carlson RE, Bergstralh EJ, Frank I, Gettman MT, Tollefson MK, Karnes RJ. Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. Int Braz J Urol. 2016 Nov-Dec; 42 (6):1091-1098
    View PubMed
  22. Parker WP, Davis BJ, Park SS, Olivier K, Choo CR, Nathan MA, Lowe VJ, Welch TJ, Zaid HB, Sobol II, Tollefson MK, Gettman MT, Boorjian SA, Mynderse LA, Karnes JR, Kwon ED. Patterns of Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: Unique Identification of Sites of Recurrence Impacting Clinical Management. Int J Radiat Oncol Biol Phys. 2016 Oct 1; 96: (2S)S112.
    View PubMed
  23. Moreira DM, Gershman B, Rangel LJ, Boorjian SA, Thompson RH, Frank I, Tollefson MK, Gettman MT, Karnes RJ. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. BJU Int. 2016 Sep; 118: (3)379-83.
    View PubMed
  24. Parker WP, Toussi A, Tollefson MK, Frank I, Thompson RH, Zaid HB, Thapa P, Boorjian SA. Risk Factors and Microbial Distribution of Urinary Tract Infections Following Radical Cystectomy. Urology. 2016 Aug; 94:96-101 Epub 2016 Apr 25
    View PubMed
  25. Toussi A, Stewart-Merrill SB, Boorjian SA, Psutka SP, Thompson RH, Frank I, Tollefson MK, Gettman MT, Carlson RE, Rangel LJ, Karnes RJ. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression? J Urol. 2016 Jun; 195: (6)1754-9.
    View PubMed
  26. Moschini M, Sharma V, Zattoni F, Boorjian SA, Frank I, Gettman MT, Thompson RH, Tollefson MK, Kwon ED, Karnes RJ. Risk Stratification of pN+ Prostate Cancer after Radical Prostatectomy from a Large Single Institutional Series with Long-Term Followup. J Urol. 2016 Jun; 195: (6)1773-8.
    View PubMed
  27. Zaid HB, Yang DY, Tollefson MK, Frank I, Winters JL, Thapa P, Parker WP, Thompson RH, Karnes RJ, Boorjian SA. Efficacy and Safety of Intraoperative Tranexamic Acid Infusion for Reducing Blood Transfusion During Open Radical Cystectomy. Urology. 2016 Jun; 92:57-62 Epub 2016 Mar 08
    View PubMed
  28. Tollefson MK. Editorial Comment. Urology. 2016 Mar; 89:67-8.
    View PubMed
  29. McEachen JC, Leng S, Atwell TD, Tollefson MK, Friese JL, Wang Z, Murad MH, Schmit GD. Percutaneous Renal Tumor Ablation: Radiation Exposure During Cryoablation and Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2016 Feb; 39: (2)233-8.
    View PubMed
  30. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Costello BA, Thompson RH, Stewart-Merrill SB, Lohse CM, Cheville JC, Leibovich BC, Tollefson MK. Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. J Urol. 2016 Feb; 195 (2):270-6 Epub 2015 Aug 18
    View PubMed
  31. Gershman B, Moreira DM, Tollefson MK, Frank I, Cheville JC, Thapa P, Tarrell RF, Thompson RH, Boorjian SA. The association of ABO blood type with disease recurrence and mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Urol Oncol. 2016 Jan; 34: (1)4.e1-9.
    View PubMed
  32. Zaid HB, Yang DY, Tollefson MK, Frank I, Parker WP, Thompson RH, Karnes RJ, Boorjian SA. Safety and efficacy of extended duration of thromboembolic prophylaxis following radical cystectomy: an initial institutional experience Urology Practice. 2016; 3: (6)462-7.
  33. Viers BR, Lightner DJ, Rivera ME, Tollefson MK, Boorjian SA, Karnes RJ, Thompson RH, O'Neil DA, Hamilton RL, Gardner MR, Bundrick M, Jenkins SM, Pruthi S, Frank I, Gettman MT. Efficiency, satisfaction, and costs for remote video visits following radical prostatectomy: a randomized controlled trial. Eur Urol. 2015 Oct; 68: (4)729-35.
    View PubMed
  34. Jaeger CD, Cockerill PA, Gettman MT, Tollefson MK. Presentation, Endoscopic Management, and Significance of Hemostatic Clip Migration into the Lower Urinary Tract Following Radical Prostatectomy. J Laparoendosc Adv Surg Tech A. 2015 Oct; 25: (10)800-3.
    View PubMed
  35. Gustafson MP, Lin Y, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2015 Sep 15; 21 (18):4224-33 Epub 2015 May 21
    View PubMed
  36. Viers BR, Houston Thompson R, Psutka SP, Lohse CM, Cheville JC, Leibovich BC, Tollefson MK, Boorjian SA. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol Oncol. 2015 Sep; 33: (9)388.e11-8.
    View PubMed
  37. Eggener SE, Badani K, Barocas DA, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston MA, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. Gleason 6 prostate cancer: translating biology into population health. J Urol. 2015 Sep; 194(3):626-34.
    View PubMed
  38. Stewart-Merrill SB, Boorjian SA, Thompson RH, Psutka SP, Cheville JC, Thapa P, Bergstrahl EJ, Tollefson MK, Frank I. Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach. Urol Oncol. 2015 Aug; 33: (8)339.e1-8.
    View PubMed
  39. Psutka SP, Boorjian SA, Moynagh MR, Schmit GD, Frank I, Carrasco A, Stewart SB, Tarrell R, Thapa P, Tollefson MK. Mortality after radical cystectomy: impact of obesity versus adiposity after adjusting for skeletal muscle wasting. J Urol. 2015 May; 193: (5)1507-13.
    View PubMed
  40. Rivera M, Granberg CF, Tollefson MK. Robotic-assisted laparoscopic surgery of urachal anomalies: a single-center experience. J Laparoendosc Adv Surg Tech A. 2015 Apr; 25(4):291-4.
    View PubMed
  41. Clifton MM, Psutka SP, Boorjian SA, Cheville JC, Thapa P, Thompson RH, Tollefson MK, Karnes RJ, Frank I. Cancer-specific mortality following radical cystectomy for bladder cancer with lymph node involvement: impact of pathologic disease features and adjuvant chemotherapy. World J Urol. 2015 Mar; 33 (3):373-9 Epub 2014 May 15
    View PubMed
  42. Psutka SP, Boorjian SA, Lohse CM, Stewart SB, Tollefson MK, Cheville JC, Leibovich BC, Thompson RH. The association between metformin use and oncologic outcomes among surgically treated diabetic patients with localized renal cell carcinoma. Urol Oncol. 2015 Feb; 33: (2)67.e15-23.
    View PubMed
  43. Knoedler JJ, Boorjian SA, Tollefson MK, Cheville JC, Thapa P, Tarrell RF, Frank I. Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy. BJU Int. 2014 Dec; 114(6):832-6.
    View PubMed
  44. Yelfimov DA, Frank I, Boorjian SA, Thapa P, Cheville JC, Tollefson MK. Adjuvant chemotherapy is associated with decreased mortality after radical cystectomy for locally advanced bladder cancer. World J Urol. 2014 Dec; 32 (6):1463-8 Epub 2014 Jan 14
    View PubMed
  45. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, Thompson RH, Tollefson MK. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014 Dec; 66: (6)1157-64.
    View PubMed
  46. Psutka SP, Stewart SB, Boorjian SA, Lohse CM, Tollefson MK, Cheville JC, Leibovich BC, Thompson RH. Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma. J Urol. 2014 Dec; 192(6):1620-7. Epub 2014 Jun 12.
    View PubMed
  47. Viers BR, Sukov WR, Gettman MT, Rangel LJ, Bergstralh EJ, Frank I, Tollefson MK, Thompson RH, Boorjian SA, Karnes RJ. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy. Eur Urol. 2014 Dec; 66: (6)1116-24.
    View PubMed
  48. Stewart SB, Cheville JC, Sebo TJ, Frank I, Boorjian SA, Thompson RH, Gettman MT, Tollefson MK, Umbriet EC, Psutka SP, Bergstralh EJ, Rangel L, Karnes RJ. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):332-7. Epub 2014 Aug 26.
    View PubMed
  49. Viers BR, Tollefson MK, Patterson DE, Gettman MT, Krambeck AE. Simultaneous vs staged treatment of urolithiasis in patients undergoing radical prostatectomy. World J Clin Cases. 2014 Nov 16; 2: (11)698-704.
    View PubMed
  50. Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urol Oncol. 2014 Nov; 32(8):1277-84. Epub 2014 Jul 10
    View PubMed
  51. Psutka SP, Carrasco A, Schmit GD, Moynagh MR, Boorjian SA, Frank I, Stewart SB, Thapa P, Tarrell RF, Cheville JC, Tollefson MK. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014 Sep 15; 120(18):2910-8. Epub 2014 May 19.
    View PubMed
  52. Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim-Chester disease. Urology. 2014 Jul; 84(1):218-21. Epub 2014 Apr 27.
    View PubMed
  53. Linder BJ, Kawashima A, Woodrum DA, Tollefson MK, Karnes J, Davis BJ, Rangel LJ, King BF, Mynderse LA. Early localization of recurrent prostate cancer after prostatectomy by endorectal coil magnetic resonance imaging. Can J Urol. 2014 Jun; 21(3):7283-9.
    View PubMed
  54. Schneider SA, Sukov WR, Frank I, Boorjian SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson MK, Jeffrey Karnes R, Cheville JC. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome. Mod Pathol. 2014 May; 27 (5):758-64 Epub 2013 Nov 01
    View PubMed
  55. Tollefson MK, Karnes RJ, Kwon ED, Lohse CM, Rangel LJ, Mynderse LA, Cheville JC, Sebo TJ. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model. Mayo Clin Proc. 2014 Mar; 89(3):308-18. Epub 2014 Jan 31.
    View PubMed
  56. Tollefson MK, Karnes RJ, Rangel L, Carlson R, Boorjian SA. Blood type, lymphadenectomy and blood transfusion predict venous thromboembolic events following radical prostatectomy with pelvic lymphadenectomy. J Urol. 2014 Mar; 191(3):646-51. Epub 2013 Oct 17
    View PubMed
  57. Eisenberg MS, Thompson RH, Frank I, Kim SP, Cotter KJ, Tollefson MK, Kaushik D, Thapa P, Tarrell R, Boorjian SA. Long-term renal function outcomes after radical cystectomy. J Urol. 2014 Mar; 191(3):619-25. Epub 2013 Sep 12
    View PubMed
  58. Wang JK, Boorjian SA, Frank I, Tarrell RF, Thapa P, Jacob EK, Tauscher CD, Tollefson MK. Non-O blood type is associated with an increased risk of venous thromboembolism after radical cystectomy. Urology. 2014 Jan; 83(1):140-5. Epub 2013 Oct 16.
    View PubMed
  59. Smith ND, Castle EP, Gonzalgo ML, Svatek RS, Weizer AZ, Montgomery JS, Pruthi RS, Woods ME, Tollefson MK, Konety BR, Shabsigh A, Krupski T, Barocas DA, Dash A, Quek ML, Kibel AS, Parekh DJ. The RAZOR (randomized open vs robotic cystectomy) trial: Study design and trial update. BJU Int. 2014; 115(2):198-205.
  60. Tollefson MK, Boorjian SA, Gettman MT, Rangel LJ, Bergstralh EJ, Karnes RJ. Preoperative estimated glomerular filtration rate predicts overall mortality in patients undergoing radical prostatectomy. Urol Oncol. 2013 Nov; 31(8):1483-8. Epub 2012 May 10.
    View PubMed
  61. Wang JK, Tollefson MK, Kim SP, Boorjian SA, Leibovich BC, Lohse CM, Cheville JC, Thompson RH. Iatrogenic splenectomy during nephrectomy for renal tumors. Int J Urol. 2013 Sep; 20(9):896-902. Epub 2013 Feb 04.
    View PubMed
  62. Kim SP, Shah ND, Weight CJ, Thompson RH, Wang JK, Karnes RJ, Han LC, Ziegenfuss JY, Frank I, Tollefson MK, Boorjian SA. Population-based trends in urinary diversion among patients undergoing radical cystectomy for bladder cancer. BJU Int. 2013 Aug; 112(4):478-84. Epub 2013 Mar 01.
    View PubMed
  63. Kim SP, Shah ND, Karnes RJ, Weight CJ, Shippee ND, Han LC, Boorjian SA, Smaldone MC, Frank I, Gettman MT, Tollefson MK, Thompson RH. Hospitalization costs for radical prostatectomy attributable to robotic surgery. Eur Urol. 2013 Jul; 64(1):11-6. Epub 2012 Aug 20.
    View PubMed
  64. Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol. 2013 Jul; 190(1):55-60. Epub 2013 Jan 09.
    View PubMed
  65. Tollefson MK, Karnes RJ, Rangel LJ, Bergstralh EJ, Boorjian SA. The impact of clinical stage on prostate cancer survival following radical prostatectomy. J Urol. 2013 May; 189(5):1707-12. Epub 2012 Nov 15.
    View PubMed
  66. Linder BJ, Frank I, Cheville JC, Tollefson MK, Thompson RH, Tarrell RF, Thapa P, Boorjian SA. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol. 2013 May; 63(5):839-45. Epub 2013 Jan 11.
    View PubMed
  67. Clifton MM, Tollefson MK. Anatomic basis of radical cystectomy and orthotopic urinary diversion in female patients. Clin Anat. 2013 Jan; 26(1):105-9. Epub 2012 Nov 30.
    View PubMed
  68. Gustafson MP, Lin Y, LaPlant B, Liwski CJ, Maas ML, League SC, Bauer PR, Abraham RS, Tollefson MK, Kwon ED, Gastineau DA, Dietz AB. Immune monitoring using the predictive power of immune profiles. J Immunother Cancer. 2013; 1:7.
    View PubMed
  69. Tollefson MK, Boorjian SA, Farmer SA, Frank I. Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease. World J Urol. 2012 Dec; 30 (6):795-9 Epub 2012 Mar 25
    View PubMed
  70. Boorjian SA, Tollefson MK, Thompson RH, Rangel LJ, Bergstralh EJ, Karnes RJ. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. J Urol. 2012 Nov; 188(5):1761-6. Epub 2012 Sep 19.
    View PubMed
  71. Kim SP, Boorjian SA, Shah ND, Karnes RJ, Weight CJ, Moriarty JP, Tollefson MK, Shippee ND, Frank I. Contemporary trends of in-hospital complications and mortality for radical cystectomy. BJU Int. 2012 Oct; 110(8):1163-8. Epub 2012 Mar 22.
    View PubMed
  72. Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP, Han LC, Borah B, Tollefson MK, Boorjian SA. The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol. 2012 Jun; 187(6):2011-7. Epub 2012 Apr 11.
    View PubMed
  73. Boorjian SA, Tollefson MK, Rangel LJ, Bergstralh EJ, Karnes RJ. Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):56-62. Epub 2011 Aug 02.
    View PubMed
  74. Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2012 Mar; 79(3):615-9.
    View PubMed
  75. Boorjian SA, Tollefson MK, Cheville JC, Costello BA, Thapa P, Frank I. Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival. J Urol. 2011 Nov; 186 (5):1796-802 Epub 2011 Sept 25
    View PubMed
  76. Tollefson MK, Frank I, Gettman MT. Robotic-assisted radical prostatectomy decreases the incidence and morbidity of surgical site infections. Urology. 2011 Oct; 78(4):827-31. Epub 2011 Jul 29.
    View PubMed
  77. Boorjian SA, Thompson RH, Tollefson MK, Rangel LJ, Bergstralh EJ, Blute ML, Karnes RJ. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol. 2011 Jun; 59(6):893-9. Epub 2011 Feb 22.
    View PubMed
  78. Tollefson MK, Gettman MT, Blute ML, Bergstralh EJ, Rangel LJ, Karnes RJ. Serum calcium is not predictive of aggressive prostate cancer after radical prostatectomy. Urology. 2011 May; 77(5):1161-5. Epub 2010 Dec 03.
    View PubMed
  79. Tollefson MK, Gettman MT, Karnes RJ, Frank I. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol. 2011 May; 185(5):1686-90. Epub 2011 Mar 21.
    View PubMed
  80. Tollefson MK, Bergstralh EJ, Rangel LJ, Karnes RJ. Predictors of outcome using salvage androgen deprivation therapy after radical prostatectomy. J Clin Oncol. 2011 Mar; 29: (7_suppl)74.
    View PubMed
  81. Shimko MS, Tollefson MK, Umbreit EC, Farmer SA, Blute ML, Frank I. Long-term complications of conduit urinary diversion. J Urol. 2011 Feb; 185(2):562-7. Epub 2010 Dec 18.
    View PubMed
  82. Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC. The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int. 2010 Dec; 106(11):1638-42.
    View PubMed
  83. Tollefson MK, Blute ML, Rangel LJ, Karnes RJ, Frank I. Lifelong yearly prostate specific antigen surveillance is not necessary for low risk prostate cancer treated with radical prostatectomy. J Urol. 2010 Sep; 184(3):925-9.
    View PubMed
  84. Tollefson M, Magera J, Sebo T, Cohen J, Drauch A, Maier J, Frank I. Raman spectral imaging of prostate cancer: can Raman molecular imaging be used to augment standard histopathology? BJU Int. 2010 Aug; 106(4):484-8. Epub 2010 Mar 01.
    View PubMed
  85. Tollefson MK, Krambeck AE, Leibovich BC, Blute ML, Chow GK. Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology. 2010 Jun; 75(6):1373-7. Epub 2009 Oct 07.
    View PubMed
  86. Tollefson MK, Blute ML, Rangel LJ, Bergstralh EJ, Boorjian SA, Karnes RJ. The effect of Gleason score on the predictive value of prostate-specific antigen doubling time. BJU Int. 2010 May; 105(10):1381-5. Epub 2009 Oct 26.
    View PubMed
  87. Tollefson MK, Elliott DS, Zincke H, Frank I. Long-term outcome of ureterosigmoidostomy: an analysis of patients with >10 years of follow-up. BJU Int. 2010 Mar; 105(6):860-3. Epub 2009 Aug 13.
    View PubMed
  88. Umbreit EC, Dozois EJ, Crispen PL, Tollefson MK, Karnes RJ, Blute ML. Radical prostatectomy for prostate cancer after ileal pouch-anal anastomosis offers oncologic control and sustains quality of life. J Am Coll Surg. 2010 Feb; 210(2):232-9. Epub 2009 Dec 03.
    View PubMed
  89. Tollefson MK, Blute ML, Farmer SA, Frank I. Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol. 2010 Jan; 183(1):81-6.
    View PubMed
  90. Routh JC, Tollefson MK, Ashley RA, Husmann DA. Iatrogenic ureteral injury: can adult repair techniques be used on children? J Pediatr Urol. 2009 Feb; 5(1):53-5. Epub 2008 Oct 21.
    View PubMed
  91. Granberg CF, Boorjian SA, Crispen PL, Tollefson MK, Farmer SA, Frank I, Blute ML. Functional and oncological outcomes after orthotopic neobladder reconstruction in women. BJU Int. 2008 Dec; 102(11):1551-5. Epub 2008 Oct 08.
    View PubMed
  92. Tollefson MK, Ashley RA, Routh JC, Husmann DA. Traumatic obliterative urethral strictures in pediatric patients: failure of the cut to light technique at long-term followup. J Urol. 2007 Oct; 178(4 Pt 2):1656-8; discussion 1658. Epub 2007 Aug 17.
    View PubMed
  93. Tollefson MK, Thompson RH, Sheinin Y, Lohse CM, Cheville JC, Leibovich BC, Kwon ED. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other. Cancer. 2007 Aug 15; 110(4):783-90.
    View PubMed
  94. Tollefson MK, Slezak JM, Leibovich BC, Zincke H, Blute ML. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc. 2007 Apr; 82(4):422-7.
    View PubMed
  95. Tollefson MK, Takahashi N, Leibovich BC. Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma. Curr Urol Rep. 2007 Jan; 8 (1):38-43
    View PubMed
  96. Tollefson M, Boorjian S, Leibovich B. Complications of the incision and patient positioning. Complications of Urologic Surgery. 2007:225-36.
  97. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006 Feb; 175(2):547-51.
    View PubMed
  98. Tollefson MK, Kawashima A, Blute ML. In situ partial nephrectomy and tumor thrombectomy for renal cell carcinoma with level II vena cava extension in a solitary kidney. Urology. 2005 Oct; 66(4):882.
    View PubMed
  99. Park JJ, Wolff BG, Tollefson MK, Walsh EE, Larson DR. Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg. 2005 Mar; 241: (3)529-33.
    View PubMed
  100. Tollefson MK, Libsch KD, Sarr MG, Chari ST, DiMagno EP, Urrutia R, Smyrk TC. Intraductal papillary mucinous neoplasm: did it exist prior to 1980? Pancreas. 2003 Apr; 26(3):e55-8.
    View PubMed